Us Bancorp \De\ Pliant Therapeutics, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 454 shares of PLRX stock, worth $644. This represents 0.0% of its overall portfolio holdings.

Number of Shares

454

Previous 564 19.5%

Holding current value

$644

Previous $6,000 16.67%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$10.55 - $15.7 $1,160 - $1,727	-110 Reduced 19.5%	454 $5,000
Q3 2024 Oct 28, 2024	SELL	$10.52 - $14.35 $3,987 - $5,438	-379 Reduced 40.19%	564 $6,000
Q2 2024 Aug 06, 2024	SELL	$10.58 - $15.61 $8,051 - $11,879	-761 Reduced 44.66%	943 $10,000
Q1 2024 May 07, 2024	BUY	$14.14 - $19.59 $11,665 - $16,161	825 Added 93.86%	1,704 $25,000
Q4 2023 Feb 09, 2024	SELL	$12.85 - $19.15 $2,043 - $3,044	-159 Reduced 15.32%	879 $15,000
Q3 2023 Nov 03, 2023	SELL	$14.58 - $20.15 $16,212 - $22,406	-1,112 Reduced 51.72%	1,038 $17,000
Q2 2023 Aug 09, 2023	BUY	$18.12 - $30.56 $23,012 - $38,811	1,270 Added 144.32%	2,150 $38,000
Q1 2023 May 09, 2023	BUY	$18.73 - $36.26 $393 - $761	21 Added 2.44%	880 $23,000
Q3 2022 Oct 27, 2022	BUY	$7.67 - $24.23 $3,137 - $9,910	409 Added 90.89%	859 $18,000
Q1 2022 May 11, 2022	SELL	$7.01 - $14.1 $1,051 - $2,115	-150 Reduced 25.0%	450 $3,000
Q4 2021 Feb 11, 2022	SELL	$12.27 - $18.26 $1,202 - $1,789	-98 Reduced 14.04%	600 $8,000
Q3 2021 Nov 10, 2021	BUY	$16.48 - $28.98 $1,615 - $2,840	98 Added 16.33%	698 $12,000
Q1 2021 Apr 28, 2021	BUY	$24.52 - $40.23 $14,712 - $24,137	600 New	600 $24,000

Others Institutions Holding PLRX

# of Institutions

172

Shares Held

64.7M

Call Options Held

228K

Put Options Held

772K

View Full List

About PLIANT THERAPEUTICS, INC.

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $69.1M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

More about PLRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account